Mirabegron, solifenacin, combined therapy, and Botox for women with overactive bladder in Taiwan
Outcome of Different Treatments of Overactive Bladder in Taiwan
This will test whether mirabegron, solifenacin, their combination, or intradetrusor Botox reduce the bladder's mechanical work and change bladder compliance in women with overactive bladder.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 30 Years to 100 Years |
| Sex | Female |
| Sponsor | Mackay Medical College Academic / other |
| Locations | 1 site (New Taipei City) |
| Trial ID | NCT07025642 on ClinicalTrials.gov |
What this trial studies
This single-center interventional study in New Taipei City applies pressure-volume analysis (PVA), a thermodynamic method adapted from cardiology, to quantify bladder mechanical work per void and to visualize compliance dynamics. Women with overactive bladder will undergo standardized urodynamic evaluations before and after treatment with mirabegron, solifenacin, combined mirabegron+solifenacin, or intradetrusor botulinum toxin A. The study compares changes in PVA-derived work and compliance metrics across treatments to determine how each therapy affects storage and voiding energetics. Patients with diabetes, prior stroke, or other significant comorbidities are excluded to reduce confounding.
Who should consider this trial
Good fit: Women with overactive bladder who can undergo urodynamic testing and who do not have diabetes, cerebrovascular disease, or other excluded medical conditions are ideal candidates.
Not a fit: Patients with diabetes, prior stroke, other excluded comorbidities, men, or those with neurogenic bladder are unlikely to be eligible and may not benefit from the study's findings.
Why it matters
Potential benefit: If successful, this could identify which therapy best lowers bladder mechanical workload and improves storage function, helping clinicians choose treatments that reduce symptoms and protect bladder health.
How similar studies have performed: Existing trials show symptomatic benefit for antimuscarinics, beta-3 agonists, and botulinum toxin, but using pressure-volume thermodynamic analysis to quantify bladder work and compliance is a novel and largely untested approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- female overactive bladder Exclusion Criteria: * DM, CVA, other medical problems
Where this trial is running
New Taipei City
- Department of Obstetrics and Gynecology — New Taipei City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Hui-Hsuan Lau, M.D.
- Email: huihsuan1220@gmail.com
- Phone: +886-975-835928
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.